Immunocytokine sequences and uses thereof

• US 7,767,405 B2
• Filed: 11/15/2006
• Issued: 08/03/2010
• Est. Priority Date: 12/17/2002
• Status: Active Grant

• Current Assignee: Merck Patent GmbH (Merck & Co., Inc.)
• Original Assignee: Merck Patent GmbH (Merck & Co., Inc.)
• Inventors: Gillies, Stephen D., Lo, Kin-Ming, Qian, Susan X.
• Primary Examiner(s): Nickol; Gary B
• Assistant Examiner(s): Xie; Xiaozhen
• Application Number:
  US11/599,687
• Publication Number:
  US 20070059282A1
• Time in Patent Office: 1,357 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/3084 against tumour-associated gangliosides
• CPC Class Codes: C07K 16/467 Igs with modifications in the FR-residues only
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.

Claims

1. A method for targeting a cell with glycosphingolipid GD2 on its surface, the method comprising administering an anti-GD2 antibody or antigen-binding fragment thereof comprising an antibody variable region comprising the amino acid sequence set forth in SEQ ID NO:

1.

2. The method of claim 1, wherein the cell is a tumor cell.

3. A method for targeting a cell with glycosphingolipid GD2 on its surface, the method comprising administering an anti-GD2 antibody or antigen-binding fragment thereof comprising an antibody variable region comprising the amino acid sequence set forth in SEQ ID NO:

2.

4. The method of claim 3, wherein the antibody or antigen-binding fragment thereof further comprises a second antibody variable region, wherein the second antibody variable region comprises the amino acid sequence set forth in SEQ ID NO:

1.